1. Benesch C, Schneider C, Voelker HU, Kapp M, Caffier H, Krockenberger M et al (2010) The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Res 30:1689–1694
2. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R (1999) Prognostic factor analysis in mycosis fungoides/Sezary sendromu. J Am Acad Dermatol 40:914–924
3. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G (1997) Quantification of tumor type m2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 17:3153–3156
4. Hoppe RT, Woods GS, Abel EA (1990) Mycosis fungoides and the Sezary syndrome: pathology, staging and, treatment. Curr Probl Cancer 14:295–371
5. Hugo F, Fischer G, Eigenbrodt E (1999) Quantification of tumor type M2 pyruvate kinase in serum and plasma. Anticancer Res 19:2753–2758